157 related articles for article (PubMed ID: 37055731)
1. Tackling reimbursement challenges to fair access to medicines - introduction to the topic.
Tachkov K; Savova A; Manova M; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(6):597-606. PubMed ID: 37055731
[TBL] [Abstract][Full Text] [Related]
2. Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis.
Son KB
Global Health; 2020 Oct; 16(1):98. PubMed ID: 33054820
[TBL] [Abstract][Full Text] [Related]
3. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
4. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
5. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications.
Godman B; Hill A; Simoens S; Selke G; Selke Krulichová I; Zampirolli Dias C; Martin AP; Oortwijn W; Timoney A; Gustafsson LL; Voncina L; Kwon HY; Gulbinovic J; Gotham D; Wale J; Cristina Da Silva W; Bochenek T; Allocati E; Kurdi A; Ogunleye OO; Meyer JC; Hoxha I; Malaj A; Hierländer C; Sauermann R; Hamelinck W; Petrova G; Laius O; Langner I; Yfantopoulos J; Joppi R; Jakupi A; Greiciute-Kuprijanov I; Vella Bonanno P; Piepenbrink JH; de Valk V; Wladysiuk M; Marković-Peković V; Mardare I; Fürst J; Tomek D; Obach Cortadellas M; Zara C; Pontes C; McTaggart S; Laba TL; Melien Ø; Wong-Rieger D; Bae S; Hill R
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):527-540. PubMed ID: 33535841
[No Abstract] [Full Text] [Related]
6. Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.
Babar ZU; Gammie T; Seyfoddin A; Hasan SS; Curley LE
Res Social Adm Pharm; 2019 Mar; 15(3):231-243. PubMed ID: 29678413
[TBL] [Abstract][Full Text] [Related]
7. The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries.
Babar ZU; Lessing C; Mace C; Bissell K
Pharmacoeconomics; 2013 Nov; 31(11):1063-82. PubMed ID: 24127259
[TBL] [Abstract][Full Text] [Related]
8. Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?
Vogler S; Salcher-Konrad M; Habimana K
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(8):867-878. PubMed ID: 37450611
[TBL] [Abstract][Full Text] [Related]
9. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
[No Abstract] [Full Text] [Related]
10. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways.
Inotai A; Kaló Z
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):627-632. PubMed ID: 31810392
[No Abstract] [Full Text] [Related]
11. Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature.
Ocran Mattila P; Ahmad R; Hasan SS; Babar ZU
Front Public Health; 2021; 9():628744. PubMed ID: 33996712
[No Abstract] [Full Text] [Related]
12. What is a fair price for a medicine? Establishing the main elements of a fair price based on the current policy debate.
Roediger A; Schönbächler G; Brand H
Public Health; 2024 Jun; 231():148-153. PubMed ID: 38692089
[TBL] [Abstract][Full Text] [Related]
13. The role of insurance policies in the drug pricing landscape.
Savova A; Manova M; Tachkov K; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):189-202. PubMed ID: 38064353
[TBL] [Abstract][Full Text] [Related]
14. Policies and availability of orphan medicines in outpatient care in 24 European countries.
Sarnola K; Ahonen R; Martikainen JE; Timonen J
Eur J Clin Pharmacol; 2018 Jul; 74(7):895-902. PubMed ID: 29632962
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
16. The "Affordable Medicines" Reimbursement Program in Ukraine: Framework Assessment and Impact Evaluation.
Dobrova V; Ratushna K; Popov O; Bezruk A; Loboda I
Value Health; 2023 Mar; 26(3):359-369. PubMed ID: 36731746
[TBL] [Abstract][Full Text] [Related]
17. Financing Strategies to Facilitate Access to High-Cost Anticancer Drugs: A Systematic Review of the Literature.
Patikorn C; Taychakhoonavudh S; Sakulbumrungsil R; Ross-Degnan D; Anantachoti P
Int J Health Policy Manag; 2022 Sep; 11(9):1625-1634. PubMed ID: 34814670
[TBL] [Abstract][Full Text] [Related]
18. Balancing access to medicines and sustainability in Europe: An analysis from the network of competent authorities on pricing and reimbursement (CAPR).
Pani L; Montilla S; Németh G; Russo P; Viceconte G; Vogler S
Pharmacol Res; 2016 Sep; 111():247-250. PubMed ID: 27293051
[No Abstract] [Full Text] [Related]
19. The Role of Indication-Based Pricing in Future Pricing and Reimbursement Policies: A Systematic Review.
Preckler V; Espín J
Value Health; 2022 Apr; 25(4):666-675. PubMed ID: 35227598
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
